E.g., 09/30/2023
E.g., 09/30/2023

BIOFIRE® Respiratory Panel 2.1 plus with SARS-CoV-2 is CE marked

15 July, 2020

CE marking of bioMérieux serology tests for SARS-CoV-2 on VIDAS®

27 May, 2020

bioMérieux serology tests for SARS-CoV-2 on VIDAS® undergo validation preceding imminent launch 

06 May, 2020

BIOFIRE® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 obtains FDA Emergency Use Authorization

04 May, 2020

bioMérieux receives Emergency Use Authorization for BIOFIRE® COVID-19 test

24 March, 2020

First of 3 diagnostic tests for  SARS-CoV-2 coronavirus available from bioMérieux

11 March, 2020

bioMérieux submits enhanced BIOFIRE® BCID2 Panel for FDA clearance

14 January, 2020

bioMérieux, a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology affiliate, has submitted to the Food and Drug Administration for 510(k) clearance of the BIOFIRE® Blood Culture Identification 2 (BCID2) Panel. The BIOFIRE® BCID2 Panel includes several additional pathogens, an expanded list of antimicrobial resistance genes, and many revised targets compared to the existing BIOFIRE® BCID Panel.d about 9,800.

World Antibiotic Awareness Week, 18-24 November, 2019

18 November, 2019

The 2019 edition of World Antibiotic Awareness Week (WAAW) will take place from November 18th – 24th. This annual campaign, organized by the World Health Organization (WHO), aims to increase awareness of drug-resistant infections  and to encourage best practices among the general public, health workers and policy makers to avoid the further emergence and spread of antibiotic resistance.

World Sepsis Day 2019

13 September, 2019

Webinar (hosted by CIDRAP): Value of Diagnostics to Enhance Antimicrobial Stewardship

16 May, 2019

CIDRAP-ASP WEBINAR NOW AVAILABLE ON-LINE

Pioneering diagnostics